Finance
Diabetes-focused therapeutics developer reports second quarter financial results
Published in Obesity and Diabetes Week, August 22nd, 2005
For the second quarter of 2005, total operating expenses were $27.6 million, compared with $18.4 million for the second quarter of 2004. Research and development (R&D) expenses increased by $9.3 million to $23.6 million, primarily due to increased costs associated with the company's expanded clinical trials and related support for its Technosphere Insulin program. General and administrative (G&A) expenses decreased by $0.1 million to $4 million.
For the first 6 months of 2005, operating expenses totaled $50.2 million, compared with $35...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Adipose Tissue
Newly discovered endocrine functions of white adipose tissue reviewed - Heart Disease Risk Factors
Cardiac dysfunction linked to altered myocardial insulin signaling - Metabolic Syndrome
Insulin receptor activator and PPAR agonist used for metabolic syndrome - Obesity and Diabetes
Adipose tissue metabolism and CD11b expression in obesity examined - Obesity and Diabetes
C-reactive protein linked to body fat and diabetes in Asian Indians - Adipose Tissue
Rosiglitazone upregulates lipases in brown adipocytes - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
